Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage CancerBusiness Wire • 04/01/21
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx TestBusiness Wire • 03/30/21
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal CancerBusiness Wire • 03/24/21
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid CancersBusiness Wire • 03/02/21
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021Business Wire • 02/24/21
Adding $5,000 to These 2 Top Stocks Could Make You Richer in 2021 (and Beyond)The Motley Fool • 02/21/21
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal CancerBusiness Wire • 02/16/21
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021Business Wire • 02/04/21
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar OutcomesBusiness Wire • 01/27/21